

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



韋俊生物科技有限公司
Wai Chun Bio-Technology Limited
(Incorporated in Cayman Islands with limited liability)
(Stock code: 0660)

PROFIT WARNING

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on preliminary assessment of the unaudited consolidated management accounts of the Group and the information currently available to the Board for the twelve months ended 31 December 2021 (the “**Management Accounts**”), the Group is expected to record a loss of not less than HK\$10,000,000.00 for the twelve months ended 31 December 2021. The loss was primarily due to the decrease in sales because of relapse of Covid-19 in Mainland China in the second half year of 2021 and the increase in finance costs which was caused by the increase in interest expenses of convertible bonds.

The Group is still in the process of preparing the second interim results for the twelve months ended 31 December 2021, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have not been finalised. The second interim results of the Group for the twelve months ended 31 December 2021 are expected to be published by the end of February 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wai Chun Bio-Technology Limited
Lam Ching Kui
Chairman and Chief Executive Officer

Hong Kong, 21 February 2022

As at the date of this announcement, the Board comprises Mr. Lam Ching Kui (Chairman) as executive Director; Mr. Chan Cheuk Ho, Mr. Wan Bo and Mr. Hau Pak Man as Independent Non-executive Directors.